Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Daiichi Sankyo
Baxter
Deloitte
Express Scripts
US Department of Justice
Chinese Patent Office
Citi

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020235

« Back to Dashboard

NDA 020235 describes NEURONTIN, which is a drug marketed by Pfizer Pharms and Parke Davis and is included in three NDAs. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the NEURONTIN profile page.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-eight drug master file entries for this compound. One hundred and eleven suppliers are listed for this compound. Additional details are available on the gabapentin profile page.
Summary for 020235
Tradename:NEURONTIN
Applicant:Pfizer Pharms
Ingredient:gabapentin
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020235
Suppliers and Packaging for NDA: 020235
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEURONTIN gabapentin CAPSULE;ORAL 020235 NDA Parke-Davis Div of Pfizer Inc 0071-0803 0071-0803-24 100 CAPSULE in 1 BOTTLE (0071-0803-24)
NEURONTIN gabapentin CAPSULE;ORAL 020235 NDA Parke-Davis Div of Pfizer Inc 0071-0805 0071-0805-24 100 CAPSULE in 1 BOTTLE (0071-0805-24)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Dec 30, 1993TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength300MG
Approval Date:Dec 30, 1993TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength400MG
Approval Date:Dec 30, 1993TE:ABRLD:Yes

Expired US Patents for NDA 020235

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Covington
Harvard Business School
Cerilliant
Argus Health
UBS
Merck
Daiichi Sankyo
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.